Quantum BioPharma Ltd.

Quantum BioPharma Ltd. is a biopharmaceutical company headquartered in Toronto, Ontario, Canada, dedicated to developing innovative assets and biotech solutions. The company's mission is to improve the quality of life for patients by developing novel solutions for brain and inflammatory disorders. It focuses on challenging neurodegenerative, metabolic, and alcohol misuse disorders.

The company's primary product candidate is Lucid-MS (formerly Lucid-21-302), a patented neuroprotective compound in development for Multiple Sclerosis (MS). Lucid-MS has demonstrated in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS, and has completed Phase 1 clinical trials. Quantum BioPharma also invented unbuzzd™, a dietary supplement designed to accelerate alcohol metabolism and reduce hangover symptoms, which it has licensed to Unbuzzd Wellness Inc., retaining ownership and royalty interests. Additionally, the company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., including real estate-secured loans and a digital asset portfolio.

In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the FDA for a Phase 2 clinical trial of Lucid-MS. Recent peer-reviewed clinical trial results for unbuzzd™ confirmed its efficacy in accelerating alcohol metabolism and reducing intoxication symptoms. Zeeshan Saeed serves as the company's CEO, appointed in June 2023. The company operates in multi-billion dollar markets for neurodegenerative diseases and alcohol misuse disorders, with a market capitalization of approximately $21.0 million as of April 2026.